Compare Merck & Co., Inc. (MRK) vs Direxion Daily TSLA Bull 2X Shares (TSLL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Direxion Daily TSLA Bull 2X Shares — how do they compare? Merck & Co., Inc. trades at $126.24 (market cap $307.25B), while Direxion Daily TSLA Bull 2X Shares trades at $11.25. The key difference: Merck & Co., Inc. pays a 2.73% dividend while Direxion Daily TSLA Bull 2X Shares pays none, and Merck & Co., Inc. is trading nearer its 52-week high, Direxion Daily TSLA Bull 2X Shares nearer its low. Which is the better fit depends on your goals.
| MRK | TSLL | |
|---|---|---|
Market Cap | $307.25B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $129.52 | $23.03 |
52-Week Low | $77.60 | $10.29 |
Enterprise Value | $350.66B | — |
Dividend Yield | 2.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.
Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.
TSLL is trading at $10.72, down 5.84% over the past day, with a bearish technical signal from moving averages and neutral oscillators. Key support lies at $10 and resistance at $11. The company has announced a future dividend of $0.10 per share scheduled for June 30, 2026. Recent news highlights focus on Tesla's upcoming earnings and related ETF movements, which may influence TSLL's performance given its thematic exposure.
The outlook for TSLL is cautious due to bearish technical indicators and reliance on Tesla's earnings catalyst. Investment opportunities hinge on positive earnings surprises from Tesla boosting the ETF, while risks include continued technical weakness and broader market volatility affecting leveraged ETF performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Direxion Daily TSLA Bull 2X Shares
TSLL provides 200% of the daily performance of Tesla, Inc. (TSLA). It uses swaps and financial derivatives to achieve its 2x leverage, making it a high-volatility tool for tactical trading rather than long-term investment due to daily resets.
Read more on TSLL →
